Our Research Results

Since we first began more than 40 years ago, Breast Cancer Trials (BCT) has contributed to more than 1,200 peer-reviewed publications and many of these research results have changed practice in the treatment and prevention of breast cancer.

The publication of the results of clinical trials research in a scientific journal or a periodic publication:

  • Fulfils the researchers’ ethical obligations to research participants and the general community;
  • Contributes to medical knowledge so doctors can make scientifically valid assessments of the benefits and risks of a new medicine or treatment for their patients.

BCT publishes study results in accordance with the BCT Publication Policy.

The citations for all of these publications are listed below, ordered by year. To search for a citation, enter a keyword/s and click search. Enclose multiple words in quotes “” to search for an exact match. Alternatively, you can search for clinical trials in a given year or for a particular clinical trial name. 

The majority of the publications can be accessed via PubMed, other research databases or publication storage systems at a university library (if you are a student/member), or directly to the journal or publication online. Many scientific journals provide articles as “open access”; however some require a subscription.



Impact of Age on Clinical Outcomes and Efficacy of Adjuvant Dual Anti-HER2 Targeted Therapy.

Lambertini M, Fielding S, Loibl S, Janni W, Clark E, Franzoi MA, Fumagalli D, Caballero C, Arecco L, Salomoni S, Ponde NF, Poggio F, Kim HJ, Villarreal-Garza C, Pagani O, Paluch-Shimon S, Ballestrero A, Del Mastro L, Piccart M, Bines J, Partridge AH, de Azambuja E. Journal of the Nation Cancer Institute. 2022; (00)(epub 5 May 2022), E-pub

Timelines to initiate a phase III trial across the globe: a sub-analysis of the APHINITY trial.

Franzoi MA, Procter M, Twelves C, Ponde N, Eiger D, Emond O, Clark E, Parlier D, Guillaume S, Reaby L, de Azambuja E and Bines J. ecancermedicalscience. 2022; 16(1379): Journal

Overall survival (OS) with first-line palbociclib plus letrozole (PAL+LET) versus placebo plus letrozole (PBO+LET) in women with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (ER+/HER2- ABC): Analyses from PALOMA-2.

Finn SR, Rugo SH, Dieras CV, Harbeck N, Im AS, Gelmon AK, Walshe JM, Martin M, MacGregor CM, Bananis E, Gauthier RE, Lu RD, Kim S, Slamon JD. Journal of Clinical Oncology 2022; 40(16 suppl):ASCO Abstract #5LBA1003, Abstract

Racial/ethnic disparities in locoregional recurrence in hormone-receptor positive node negative breast cancer patients enrolled in the TAILORx trial.

Kantor O, King AT, Freedman AR, Mayer LE, MacGregor MC , Korde AL, Sparano AJ, Mittendorf AE. Journal of Clinical Oncology. 2022; 40(16 suppl):ASCO Abstract #515, Abstract

Primary results of ANZ 1002: Post-operative radiotherapy omission in selected patients with early breast cancer trial (PROSPECT) following pre-operative breast MRI.

Mann B, Rose A, Hughes J, Skandarajah AR, Murugasu A, Spillane AJ, Chua BH, Zdenkowski N, Braggett H, Badger H, Eggins R, Gebski V, Park A, Schwartz K, Mou A, Collins J. Journal of Clinical Oncology. 2022; 40(16 suppl):ASCO Abstract #572, Abstract

Impact of body mass index on treatment and outcomes in patients with early hormone receptor-positive breast cancer receiving endocrine therapy with or without palbociclib in the PALLAS trial.

Pfeiler G, Hlauschek D, Mayer E, Deutschmann C, Kacerovsky-Strobl S, Martin M, Meisel JL, Zdenkowski N, Loibl S, Balic M, Park H, Prat A, Isaacs C, Machacek-Link J, Schurmans C, Theall K P, Fesl C, Dueck CA, DeMichele A, Gnant M. Journal of Clinical Oncology. 2022; 40(16 suppl):ASCO Abstract #518, Abstract

Total Publications: 1244